- Open
- 53.50
- High
- 52.78
- Low
- 52.30
- Close
- 52.78
- Change
- -1.50 (-2.80%)
- Volume
- 23,020
| 13 Jul 2026 | 07:00:11 | Portfolio Update and Presentation |
| 1 Jul 2026 | 07:00:05 | Portfolio Update: Glycotest and ProAxsis |
| 17 Jun 2026 | 14:32:46 | Result of AGM |
| 22 May 2026 | 12:38:58 | Posting of Annual Report and Notice of AGM |
| 3 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 12 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 27 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
EMV Capital Plc is a venture capital investor focused on the deep tech and life sciences sectors, operating both in the UK and internationally. The company engages in identifying and investing in early-stage companies, aiming to deliver long-term value for its shareholders through a capital-efficient investment model. EMV Capital also emphasizes ethical corporate culture and stakeholder engagement, ensuring that its investment practices align with responsible and transparent values.
| 13 Jul 2026 | 07:00:11 | Portfolio Update and Presentation |
| 1 Jul 2026 | 07:00:05 | Portfolio Update: Glycotest and ProAxsis |
| 17 Jun 2026 | 14:32:46 | Result of AGM |
| 22 May 2026 | 12:38:58 | Posting of Annual Report and Notice of AGM |
| 3 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 12 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 27 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
EMV Capital Plc is a venture capital investor focused on the deep tech and life sciences sectors, operating both in the UK and internationally. The company engages in identifying and investing in early-stage companies, aiming to deliver long-term value for its shareholders through a capital-efficient investment model. EMV Capital also emphasizes ethical corporate culture and stakeholder engagement, ensuring that its investment practices align with responsible and transparent values.
| 21 May 2026 |
| 07:00:09 |
| AMR Bio: Commercial Update |
| 30 May 2026 |
| EMV Capital and advances with AMR Bio’s XF-73 drug - ICYMI |
| 28 May 2026 | EMV Capital advances XF-73 toward late-stage trials for surgical infection prevention |
| 21 May 2026 | IXICO, Ilika, EMV Capital, Zephyr Energy, Metals One, Bradda Head Lithium - Small Cap Snapshot |
| 21 May 2026 | EMV Capital's AMR Bio advances infection-prevention drug towards phase III trial |
| 19 May 2026 | Thor Explorations, IXICO, EMV Capital, Empire Metals, Coiled Therapeutics - Small Cap Snapshot |
| 19 May 2026 | EMV Capital grows assets under management to £112.5m as venture platform scales |
| 21 May 2026 |
| 07:00:09 |
| AMR Bio: Commercial Update |
| 30 May 2026 |
| EMV Capital and advances with AMR Bio’s XF-73 drug - ICYMI |
| 28 May 2026 | EMV Capital advances XF-73 toward late-stage trials for surgical infection prevention |
| 21 May 2026 | IXICO, Ilika, EMV Capital, Zephyr Energy, Metals One, Bradda Head Lithium - Small Cap Snapshot |
| 21 May 2026 | EMV Capital's AMR Bio advances infection-prevention drug towards phase III trial |
| 19 May 2026 | Thor Explorations, IXICO, EMV Capital, Empire Metals, Coiled Therapeutics - Small Cap Snapshot |
| 19 May 2026 | EMV Capital grows assets under management to £112.5m as venture platform scales |